Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve unaudited quarterly financial ....
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Ltd has scheduled a Board Meeting on February 11, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3 FY26). The Board will also consider increasing the Authorised Capital of the company and recommending the issue of Bonus Shares to existing equity shareholders, both subject to member approval. Additionally, the Board will finalise the date, venue and time of an Extra-Ordinary General Meeting, set the Record Date, and appoint a scrutinizer for the e-voting process. The trading window for insiders is already closed since January 1, 2026 and will reopen 48 hours after the results are announced.
Investors should watch for Q3 FY26 earnings on February 11, 2026. The proposal of Bonus Shares and increase in Authorised Capital signals a potential capital restructuring, which could be viewed positively by shareholders if approved at the EGM.